RxDoctor Payments Data

Steven Karner, MD

Neurology · Charlotte, NCNPI 1821052945

Payments from drug & device makers

$2,887in general payments, 2019–2025

Across 32 payments — averaging $90.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$706
  • AbbVie$466
  • Genentech, Inc.$366
  • Biogen$284
  • Teva Pharmaceuticals USA, Inc.$261
  • Bristol Myers Squibb$124
  • plus $681 from 9 others

What the payments were for

  • Food & beverage$2,79197%
  • Education$963%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,887 in reported general payments places this provider in the 60th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$83,172
Medicare patients
364
Services billed
560

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XcopriCenobamate95$191,046
FycompaPerampanel97$146,719
EpidiolexCannabidiol (Cbd)22$133,200
KeppraLevetiracetam38$112,283
LamictalLamotrigine38$69,040
VimpatLacosamide30$51,838
Lamictal XrLamotrigine18$47,670
OnfiClobazam13$37,924
Oxtellar XrOxcarbazepine14$33,487
TopamaxTopiramate20$32,247
BriviactBrivaracetam19$30,255
Nurtec OdtRimegepant Sulfate16$25,432
Aimovig AutoinjectorErenumab-Aooe24$22,981
Lacosamide110$22,133
Carbamazepine ErCarbamazepine145$21,180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$706$191,04695 claims
Eisai Inc.Fycompa$19$146,71997 claims
UCB, Inc.Vimpat, Briviact, Nayzilam$92$100,40874 claims
Lundbeck LLCOnfi$97$37,92413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 566 neurology providers in North Carolina.

Other neurology in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →